ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Nashville, TN, USA:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Nashville, Tennessee, United States and 16 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Nashville, Tennessee, United States and 41 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 75 other locations

at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...

Enrolling
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: cemsidomide

Phase 1, Phase 2

C4 Therapeutics

Nashville, Tennessee, United States and 12 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Nashville, Tennessee, United States and 37 other locations

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...

Active, not recruiting
Diffuse Large B Cell Lymphoma (DLBCL)
Biological: bbT369

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Nashville, Tennessee, United States and 3 other locations

receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non...

Enrolling
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Biological: JNJ-90014496

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Nashville, Tennessee, United States and 27 other locations

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed orig...

Enrolling
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib

Phase 4

Lilly
Lilly

Nashville, Tennessee, United States and 35 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Nashville, Tennessee, United States and 6 other locations

This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non...

Active, not recruiting
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Extranodal NK/T-cell Lymphoma
Drug: CD30.CAR-T

Phase 1

Tessa Therapeutics

Nashville, Tennessee, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems